Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Genprex Inc
(NQ:
GNPX
)
2.200
-0.010 (-0.45%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Genprex Inc
< Previous
1
2
3
4
5
6
7
Next >
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bell Podcast
July 06, 2023
Via
Investor Brand Network
Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3
July 06, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Chinese Patent, Exclusivity for REQORSA(R) Gene Therapy Combination in Many of the Largest Markets
July 05, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Genprex Inc.’s (NASDAQ: GNPX) Inspiring Patient Video on Gene Therapy’s Potential in NSCLC Treatment
June 02, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives Fast Track Designation for Proprietary Immunogene Therapy
June 28, 2023
Via
Investor Brand Network
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 28, 2023
Via
Benzinga
Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode
June 23, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors
June 20, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NSCLC Landscape
June 16, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORSA(R) Immunogene Therapy for Late-Stage Non-Small Cell Lung Cancer
June 14, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Chief Medical Officer Featured Guest on Latest Bell2Bell Release
June 08, 2023
Via
Investor Brand Network
BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREX(R) Nanoparticle Delivery System
June 07, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Video Featuring Clinical Trial Patient Sharing Study Experience
June 02, 2023
Via
Investor Brand Network
Genprex (NASDAQ:GNPX) Releases New Patient Video Interview Describing Positive Experience In Clinical Trial
June 02, 2023
Via
ACCESSWIRE
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
June 01, 2023
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that...
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Receives SRC Approval to Advance to Phase 2 Portion of REQORSA(R) Clinical Trial
May 30, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Results of Phase 1 Clinical Trial Will Be Published at ASCO Meeting
May 26, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Video Featuring Chief Medical Officer Discussing Positive Preclinical Data with NPRL2 Gene Therapy
May 23, 2023
Via
Investor Brand Network
Genprex Inc. (NASDAQ: GNPX) Research Collaborators Present Positive Preclinical Data at American Association of Cancer Research 2023 Annual Meeting
May 17, 2023
Via
Investor Brand Network
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate and Present at Upcoming May Industry and Investor Conferences
May 08, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Crude Oil Up 1.5%; Philips Shares Jump After Q1 Results
April 24, 2023
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping around 40 points on Monday. The Dow traded up 0.05% to 33,827.42 while the NASDAQ fell 0.33% to 12,032.16....
Via
Benzinga
Why IDEAYA Biosciences Shares Are Trading Higher By Around 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 24, 2023
Gainers Aclarion, Inc. (NASDAQ: ACON) shares surged 152% to $1.85 amid the publication of durability data for the company's back pain treatment.
Via
Benzinga
US Stocks Turn Lower; Nasdaq Dips 100 Points
April 24, 2023
U.S. stocks turned lower midway through trading, with the Nasdaq Composite dropping around 100 points on Monday. The Dow traded down 0.19% to 33,744.92 while the NASDAQ fell 0.84% to 11,971. The S&P...
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Data Supporting Therapeutic Potential of Its Non-Viral Delivery System
April 19, 2023
Via
Investor Brand Network
Genprex Touts Encouraging Preclinical Data From Lung Cancer Candidate
April 19, 2023
Genprex Inc (NASDAQ: GNPX) announced that its research collaborators presented preclinical data for the NPRL2 gene (also known as the TUSC4 gene).
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
April 19, 2023
Via
Benzinga
Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket
April 19, 2023
Gainers Clearmind Medicine Inc. (NASDAQ: CMND) jumped 69.3% to $0.8480 in pre-market trading after dropping 12% on Tuesday. Clearmind Medicine recently announced a $3.5 million public offering priced...
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Research Findings, Additional Support for REQORSA(R) and Its Therapeutic Potential
April 18, 2023
Via
Investor Brand Network
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Provides Statement Regarding FDA Initiative to Accelerate Approval Process for Gene Therapies
March 23, 2023
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.